Literature DB >> 19236744

[Expression of cyclooxygenase-2 in bone marrow cells of leukemia patients and its association with angiogenesis].

Xue-Wen Liu1, Qi-Tu He, Zhi-Qin Li, Hong-Jie Ma, Jing Li, Guo-Rong Jia, Yan Lu, Hai-Yan Han, Zhe Li, Yan Yun, Dong-Xia Zhang.   

Abstract

The objective of this study was to investigate the effect of cyclooxygenase-2 (COX-2) in the angiogenesis of bone marrow in leukemia patients. 51 patients with newly diagnosed acute leukemia were taken as study objects, 18 healthy volunteers were enrolled in the control group. Bone marrow microvessel density (MVD) in bone marrow biopsy tissue section was determined with immunohistochemistry method, the vascular endothelial growth factor level in serum was detected with ELISA method and the expression of cyclooxygenase-2 in bone marrow cells was assayed by flow cytometry. The results showed that the MVD, VEGF level, positive rate of COX-2 expression in leukemia group all obviously increased as compared with the control group (p < 0.05). The correlative coefficients of MVD, VEGF level and COX-2 expression rate were 0.614, 0.423 and 0.577 respectively (p < 0.05). In conclusion, as well as solid tumors, leukemia may be also a angiogenesis-dependent malignant tumor. Coordination of COX-2 with VEGF may promote angiogenesis in bone marrow.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19236744

Source DB:  PubMed          Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi        ISSN: 1009-2137


  3 in total

Review 1.  Does celecoxib improve the efficacy of chemotherapy for advanced non-small cell lung cancer?

Authors:  Leng-Chen Hou; Fang Huang; Hong-Bin Xu
Journal:  Br J Clin Pharmacol       Date:  2015-11-02       Impact factor: 4.335

2.  Efficacy and safety of COX-2 inhibitors for advanced non-small-cell lung cancer with chemotherapy: a meta-analysis.

Authors:  Ping Dai; Jing Li; Xiao-Ping Ma; Jian Huang; Juan-Juan Meng; Ping Gong
Journal:  Onco Targets Ther       Date:  2018-02-05       Impact factor: 4.147

3.  Comparison of the benefits of celecoxib combined with anticancer therapy in advanced non-small cell lung cancer: A meta-analysis.

Authors:  Wei Zhang; Lilan Yi; Jie Shen; Hongman Zhang; Peng Luo; Jian Zhang
Journal:  J Cancer       Date:  2020-01-20       Impact factor: 4.207

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.